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TECHNICAL NOTE
Measurement of GFR with non-radioisotopic radio contrast
agents
WILLIAM DALMEIDA and WAD! N. SUKI
Renal Section, Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
Measurement of GFR with non-radioisotopic radioeontrast agents. The
clearance of creatinine has been shown to overestimate GFR in patients
with renal disease and in kidney transplant recipients. Alternate means
for measuring GFR involve the use of constant infusion and, frequently,
of radioisotopes. We report herein the measurement of GFR with the
use of a radiocontrast agent (diatrizoote meglumine) injected subcuta-
neously with a small amount of epinephrine (0.05 ml of I : 1000). The
concentrations of this marker of glomerular filtration in blood and in
urine were measured with high-performance liquid chromatography.
The results demonstrate that with this method of administration stable
blood levels are observed for at least three hours. Furthermore,
creatinine clearance overestimated GFR by 50% and by 68% in patients
with renal disease and in renal transplant recipients, respectively. This
method offers several advantages: I) the use of commonly available and
inexpensive materials; 2) obviates the need for the use of constant
infusions; and 3) avoids the use of radioisotopes.
The two most widely used markers for the measurement of
GFR are inulin and creatinine. The measurement of inulin
clearance suffers from the need to infuse patients constantly
with inulin intravenously, laborious sample preparation, and
the non-specificity of the inulin colorimetric assay [1]. The
clearance of endogenous creatinine, derived from catabolism of
creatine and phosphocreatine [21, suffers from its overestima-
tion of GFR in certain disease states [3], and the lack of
specificity of the colorimetric assay employed in its determina-
tion [41.
Measurement of GFR was markedly simplified by the intro-
duction of radio-labeled iothalamate which is handled by the
kidney in a fashion similar to inulin [5—71. The method was
further simplified by utilizing a single subcutaneous injection of
'251-iothalamate mixed with 0.1 ml of 1:1000 epinephrine [81.
The major drawbacks of this technique are those associated
with the use of radio-labeled compounds such as radioisotope
handling, storage and disposal, detection and patient and staff
exposure.
In 1984, a simple HPLC micro-method for the determination
of iothalamate was developed which eliminated the need for the
use of radio-labeled compounds [9]. In the present study we
used Hypaque meglumine 60% (diatrizoate meglumine injec-
tion) which is a commercially available contrast dye (Winthrop
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Laboratories). The advantages to using Hypaque meglumine
are that it is relatively inexpensive, approved for human use,
commercially available, can be used employing the single
subcutaneous injection method, and it is detectable by the
HPLC micro-method.
Methods
Simultaneous clearance studies were performed, with Hy-
paque meglumine and creatinine, on normal subjects, patients
with renal disease, and kidney transplant recipients. Subjects
were given a waterload (20 mI/kg body wt) and urinary output
was replaced with water. Subjects were injected subcutane-
ously in the deltoid region with 1 cc of sterile 60% Hypaque
meglumine (Winthrop Laboratories, New York City, New
York, USA) mixed with 0.05 cc of 1: 1000 epinephrine. After a
45 to 60 minute equilibration period, the patients voided and the
clearance timing began. Three 30-minute clearance periods
were then collected with a blood sample drawn at the midpoint
of each period. Urine samples were collected by voluntary
voiding and venous blood samples were collected in heparin-
ized vacuum tubes. Samples were then centrifuged and aliquots
were analyzed immediately or frozen for analysis at a later time.
The samples were analyzed by HPLC according to a previously
published method [9]. The determination of Hypaque meglu-
mine (60% sterile injection, Winthrop) is performed using a
Perkin-Elmer HPLC system (Norwalk, Connecticut, USA)
which consists of: Perkin-Elmer Series 4 pump system, Perkin-
Elmer LC-75 variable wavelength detector (set at 254 nm, 0.02
a.u.f. S.), Perkin-Elmer LCI- 100 computing integrator (chart
speed 3 mm/mm) and a Waters 30 cm u-Bond pack C,8
Reversed Phase Column (particle size 10 jim, I.D. 4.1 mm). The
mobile phase consists of 3.5 parts acetonitrile and 96.5 parts
0.04% phosphoric acid (HPLC grade, Fisher Scientific, Pitts-
burgh, Pennsylvania, USA) and a flow rate of 0.8 mllmin to 1.5
ml/min.
Samples are deproteinized by the addition of 200 l.d
acetonitrile to 100 1.d of plasma and then vortexing. The sample
is then centrifuged for five minutes at 1000 rpm. The clear
supernatant is collected and 5 l aliquots are injected into the
column. The concentration of hypaque meglumine is then
determined by comparing peak heights of samples to the
standard curves provided by the LCI-l00.
Hypaque meglumine and creatmnine clearances were calcu-
lated using the standard formula.
725
726 Dalmeida and Suki: GFR measurement without infusion or isotopes
0 50 100 150 200 250 300 350 400
Hypaque meglumine, jig/mi
Fig. 2. A plot of the peak height (in arbitrary units) on HPLC versus
the concentration of Hypaque meglumine. Note the excellent correla-
tion in the range of concentrations encountered in urine.
Subjects and patients studied were as follows: eight normal
volunteers (5 males, 3 females, age 25 to 53 years, mean 35.4
years), five patients (5 males, age 21 to 63 years, mean 44.6
years) with renal disease (one each with polycystic kidney
disease, Henoch-SchOnlein purpura, and obstructive nephrop-
athy, and two with glomerulonephritis), and six recipients (1
male, 5 females, age 29 to 51 years, mean 40.8 years) of a renal
transplant (three receiving azathioprine and three receiving
cyclosporine).
Results
Standard curves
Standard curves were constructed using human plasma and
urine spiked with known concentrations of Hypaque meglumine
(Figs. 1 and 2). The concentrations ranged from 6.25 g/ml to 50
g/rnl for plasma and 12.5 g/ml to 400 g/ml for urine. The
correlation coefficients for each curve are 0.999 and 0.998,
respectively.
Blood levels
Normal subjects were divided into two subgroups: one (3
subjects) receiving Hypaque meglumine mixed with 1: 1000
epinephrine, and the other (5 subjects) receiving Hypaque
meglumine only. The plasma concentrations of Hypaque
meglumine for both groups are shown in Figure 3. It should be
noted that the group receiving the 1: 1000 epinephrine had lower
plasma concentrations, probably due to local vasoconstriction
and slower absorption of the Hypaque meglumine from the
injection site. The group given Hypaque meglumine only shows
a significant decrease in Hypaque plasma concentration by the
third clearance period, whereas the group receiving Hypaque
and 1: 1000 epinephrine demonstrated a rather stable plasma
concentration with a slight but insignificant increase by the last
period. When each group's Hypaque clearance was compared
to its creatinine clearance, for each period, there were no
significant differences found and the two subgroups were com-
bined for the purposes of further analysis.
The plasma concentrations in the patients with renal disease
and in the renal transplant recipients are shown in Figure 4
(along with the mean blood values for the normal volunteers). It
can be seen that the mean serum values in each of the three
clearance periods were higher in the renal disease patients than
in the transplant recipients, which is consistent with the gener-
ally lower glomerular filtration rate in the former group than in
the latter. The plasma level of meglumine tended to rise slightly
in the third period in both groups, but the mean values in none
of the periods was significantly different from those in the other
two.
The mean serum creatinine values in the three groups were
0.94 0.05 mg/dl in the normal subjects, and 5.18 1.18 and
3.36 0.58 in the renal disease and transplant groups, respec-
tively. The latter two values were significantly higher than the
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Fig. 3. A plot of the concentration of Hypaque meglumine in the sera
of normal volunteers in the three clearance periods. Subjects were
given Hypaque meglumine subcutaneously with (0, N = 5) or without(•, N = 3) 0.05 ml of I : 1000 epinephrine. Note the stability of the
serum vahies in the group given epinephrine.
Fig. 1. A plot of the peak height (in arbitrary units) on HPLC versus
the concentration of Hypaque negluinine. Note the excellent correla-
tion in the range of concentrations encountered in serum.
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normal (P < 0.05 and <0.034, respectively) but not significantly
different from each other.
Renal function
The clearances of creatinine (CCR) and of meglumine (CM)
and the CCR/CM ratios are shown in Table 1. Both groups of
patients had impaired renal function, when compared to normal
control subjects, as measured by either technique. However,
whereas the CCRICM was 0.97 0.05 in the normal subjects,
indicating the virtual equality of function as measured by either
method, the CCR greatly exceeded the CM in the renal disease
and the renal transplant patients. The ratios of 1.50 0.22 and
1.68 0.17 in the two groups, respectively, are significantly
higher than the ratio in the normal controls. Overestimation of
renal function by 20% or more (ratio >1.2) was observed in
none of the normal controls, while in 9 of the 11 patients with
renal disease or recipients of renal transplants renal function
was overestimated (chi-square test, = 9.3710, P < 0.0022).
Discussion
In the present report we describe a simple new method for the
determination of glomerular filtration rate. This method em-
ploys commonly available agents, namely meglumine diatrizo-
ate and 1: 1000 epinephrine, requires no constant infusion, and
the marker of glomerular filtration is relatively easy to measure
using HPLC. Using the subcutaneous route for administration
of meglumine, with a small dose (0.05 ml) of I : 1000 epineph-
rifle, resulted in blood levels of this marker that were fairly
constant for as long as three hours. Using this technique in
normal control subjects showed the clearances of creatinine and
of meglumine to be virtually identical (CCR/CM = 0.97). Al-
though this technique is a modification of one described previ-
ously in which '251-iothalamate was used [8], it has the advan-
tage of not using isotopic materials. The use of radioisotopes
requires special licensing and the compliance with stringent
rules governing handling, storage and disposal of contaminated
wastes. The use of commercially-available radiocontrast agents
simplifies the procedure and makes it easy to perform the
Subjects N
Creatinine
clearance
Meglumine
clearance CCR/CM ratio
Normal 8 110.8 4.7 115.6 6.1 0.97 0.05
Renal disease 5 48.6 37.6 26.1 17.9 1.50 0.22a
Renal transplant 6 34.7 10.6 21.9 7.7 1.68 017b
clearance procedure in any clinical setting, be it an outpatient
clinic, a patient's hospital room or a laboratory not licensed for
the use of radioisotopes. Although this was not done in the
present study, this method offers the additional advantage of
being able to simultaneously measure the clearance of para-
aminohippurate (PAH), a measure of renal plasma flow, since
PAH can be measured, along with meglumine, by HPLC in the
same biological sample [9].
We also demonstrated in the present report the marked
discrepancy between the creatinine clearance and the meglu-
mine clearance in patients with renal disease and in renal
transplant recipients. In these two groups the creatinine clear-
ance exceeded the meglumine clearance by 50% and 68%,
respectively. This discrepancy is probably the result of creati-
nine secretion since it largely can be eliminated by blockade of
tubular creatinine secretion with intravenous cimetidine, an-
other organic base [101. Overestimation of the rate of glomeru-
lar filtration by measurement of creatinine clearance in patients
with renal disease [10, 11] and renal transplant recipients (12)
has been reported by a number of investigators. Shemeth et al
[10] reported a creatinine clearance to inulin clearance ratio of
1.64 in a large number of patients with various glomerular
diseases. Such a discrepancy was not observed when 99mTc
DTPA or dextran were used as markers of glomerular filtration
and compared to the clearance of inulin. A similar enhancement
of creatinine clearance (ratio of 1.51) compared to the clear-
ances of mTcDTPA and inulin was reported in heart trans-
plant recipients with depressed renal function as a result of
cyclosporine-induced chronic nephropathy [111. In cadaveric
kidney transplant patients receiving cyclosporine, the ratio of
creatinine to 99mTcDTPA clearances was found to be 1.38 [12].
Our study, therefore, is in agreement with other studies using
radioisotopic (99mTCDTpA) or chemical (inulin) markers of
glomerular filtration, both of which require constant infusion. In
addition to the difficulties with the use of radioisotopes dis-
cussed earlier, the chemical analysis of inulin is tedious [1].
Although we did not attempt in the present study to demon-
strate the equivalence of meglumine clearance to the clearance
of inulin in patients with abnormal renal function, the equiva-
lence of the clearance of a related substance, iothalamate, to
that of inulin had been previously reported in normal subjects
and in patients with impaired renal function [5]. Furthermore,
the degree of overestimation of glomerular filtration by creati-
nine clearance in other studies [10—12] was similar to that
observed in the present study. This evidence put together
suggests strongly that the clearance of meglumine is an accurate
measure of glomerular filtration both in normal subjects and in
patients with depressed renal function.
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Table 1. The mean values for creatinine clearances (CCR) and
meglumine clearances (CM), and CCR/CM ratio in all three groups
studied
Significantly different from control: a p < b p < 0.034
1 2
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Fig. 4. A plot of the concentration of Hypaque meglumine in the sera
of normal volunteers (combined values from Fig. 3, U, N = 8), patients
with renal disease, (0, N = 5) and renal transplant recipients (•, N =
6). Note the stability of the serum values in all three groups, and the
higher levels in the patients with impaired renal function.
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Our findings of a discrepancy between the clearances of
creatinine and of meglumine in renal transplant recipients,
however, are at variance with those reported for iothalamate in
both kidney donors and recipients [13]. Rosenbaum et al [13]
reported a ratio of iothalamate to creatinine clearances of 0.95
in kidney recipients, whereas the ratio of creatinine to inulin
clearances was 1.51 in this population. They proposed that
inulin was an inadequate marker of glomerular filtration in these
patients. The reasons for this discrepancy are not immediately
apparent, and its resolution shall await the simultaneous mea-
surement of the clearances of iothalamate, meglumine and
inulin in a group of transplant recipients and donors.
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